CLINICAL_TRIALS
trial_result
· 2015-05-29
Clinical Trial Update: Natalizumab (Tysabri) Re-Initiation of Dosing [Phase 3]
Summary
The Phase 3 trial of natalizumab (Tysabri) for relapsing-remission multiple sclerosis was terminated, with results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2015-05-29